EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The SGLT2 Inhibitor Canagliflozin Promotes β‐Cell Regeneration and Restores and Stabilises β‐Cell Identity in a Polygenic Model of Severe Early‐Onset Type 2 Diabetes

Iuliana Popescu iD, Robert C Bunn, Phil Ray, Kathryn M Thrailkill, John L Fowlkes

Journal of Cellular and Molecular Medicine · 2026-03 · 30 (5)

DOI: 10.1111/jcmm.71041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 11.03.2026. Verfasst von Iuliana Popescu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Barnstable Brown Diabetes Center, College of Medicine, University of Kentucky, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Canagliflozin, Insulin-Secreting Cells, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, University of Kentucky Barnstable Brown Diabetes Center Pediatric Laboratory Endowment., National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Childhood obesity has led to an increase in type 2 diabetes (T2D) among youth, with adolescent‐onset T2D showing a rapid decline in β‐cell function compared to adult‐onset cases. While the disease progression is more aggressive in early life, treatment can lead to recovery or remission more often at younger ages. SGLT2i have proven multiple health benefits when prescribed to adults with T2D but may have a greater potential in improving insulin production and β‐cell mass in youth. In our study, TallyHO mice, which develop severe early‐onset T2D, were treated with canagliflozin (cana) while on a 10‐week diet. Results showed a significant reduction in blood glucose levels and improved β‐cell function, indicated by higher C‐peptide, islet insulin content, and HOMA‐B index compared to untreated mice. Cana treatment restored the islet area and β to α‐cell ratio, while also decreasing apoptosis. Notably, cana promoted the transient appearance of endocrine bihormonal cells and small clusters of insulin‐positive cells, suggesting a possible transdifferentiation process and β‐cell neogenesis. Furthermore, cana stabilised β‐cell phenotype, restoring the expression of key identity markers while reducing abnormal cell types and the dedifferentiation to precursors and mesenchymal cells. These findings suggest that canagliflozin can promote the regeneration of pancreatic islets and mitigate β‐cell dedifferentiation in the early onset of β‐cell deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinInsulin-Secreting CellsDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRegenerationAnimalsMiceBlood GlucoseDisease Models, AnimalInsulinMaleHumansApoptosis

Stichwörter der Autor:innen

SGLT2canagliflozinpaediatric diabetespancreatic isletregenerationβ‐cell

Substanzen

CanagliflozinSodium-Glucose Transporter 2 InhibitorsBlood GlucoseInsulin

Autor:innen und Institutionen

  • Barnstable Brown Diabetes Center, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
  • Department of Pediatric Endocrinology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
  • Barnstable Brown Chair in Pediatric Diabetes Research, College of Medicine, Lexington, Kentucky, USA.

ORCID-Profile: Iuliana Popescu

Förderung

  • NIH HHS
  • University of Kentucky Barnstable Brown Diabetes Center Pediatric Laboratory Endowment.
  • National Institutes of Health

Zitieren

APA

Popescu, I., Bunn, R. C., Ray, P., Thrailkill, K. M., & Fowlkes, J. L. (2026). The SGLT2 Inhibitor Canagliflozin Promotes β‐Cell Regeneration and Restores and Stabilises β‐Cell Identity in a Polygenic Model of Severe Early‐Onset Type 2 Diabetes. Journal of Cellular and Molecular Medicine, 30(5). https://doi.org/10.1111/jcmm.71041

Vancouver

Popescu I, Bunn RC, Ray P, Thrailkill KM, Fowlkes JL. The SGLT2 Inhibitor Canagliflozin Promotes β‐Cell Regeneration and Restores and Stabilises β‐Cell Identity in a Polygenic Model of Severe Early‐Onset Type 2 Diabetes. Journal of Cellular and Molecular Medicine. 2026;30(5). doi:10.1111/jcmm.71041

BibTeX
@article{Popescu2026,
  author = {Popescu, Iuliana and Bunn, Robert C and Ray, Phil and Thrailkill, Kathryn M and Fowlkes, John L},
  title = {The SGLT2 Inhibitor Canagliflozin Promotes β‐Cell Regeneration and Restores and Stabilises β‐Cell Identity in a Polygenic Model of Severe Early‐Onset Type 2 Diabetes},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {5},
  doi = {10.1111/jcmm.71041}
}
Kostenlos starten →